linjc16/ctgov huggingface dataset:
Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control

Study Overview
=================
Brief Summary
-----------------
Fimasartan and Rosuvastatin for hypertension and dyslipidemia control

Official Title
-----------------
A Single-center Cross-sectional Study to Evaluate the Effectiveness of Antihypertensive Treatment Including Fimasartan and the Dyslipidemia Treatment Including Rosuvastatin and to Assess the Association Between the Two Treatments

Conditions
-----------------
Cardiovascular Diseases, Hyperlipidemias

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hypertension patients who are taking an anti-hypertensive agent, including Fimasartan at least 12 weeks or more. Dyslipidemia patients who are taking dyslipidemia drug, including Rosuvastatin at least 12 weeks or more Patients who has blood pressure and lipid levels (Total cholesterol, LDL-C, HDL-C, non-HDL-C, * TG) checks 2 weeks before registration Exclusion Criteria: Patients being hospitalized Patients who stop taking Fimasartan or Rosuvastatin within 12 weeks 14 or more consecutive days Patients who have more than 400mg/dl triglyceride(TG) at the registration time

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Co-relation between blood pressure and dyslipidemia | Check the blood pressure and dyslipidemia control rates, also check the correlation between these two disease | 12 weeks |
Bariatric Surgery and Pharmacokinetics of Escitalopram

Study Overview
=================
Brief Summary
-----------------
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on escitalopram are investigated.

Official Title
-----------------
Bariatric Surgery and Pharmacokinetics Escitalopram: BAR-MEDS Escitalopram

Conditions
-----------------
Obesity, Morbid

Intervention / Treatment
-----------------
* Drug: Escitalopram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway Being a Norwegian citizen Exclusion Criteria: Having previously undergone resections in the GI-tract

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Escitalopram|Patients are tested for their normal prescription escitalopram medication|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Escitalopram concentration in blood serum (area under curve (AUC)) |  | From baseline to 1 year postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bariatric surgery, Gastrointestinal tract, Biological availability, Pharmacokinetics, Citalopram
A Study in Healthy Volunteers to Evaluate Serum and Urine Levels of the Investigational Product Versus Comparator.

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to obtain initial pharmacokinetic data in healthy patients after dosing a combination of the study medications.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Fluticasone Propionate
* Drug: Formoterol Fumarate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-smokers, BMI 18-29, no current medications Exclusion Criteria: Significant conditions or disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Fluticasone Propionate|nan|
|Drug: Formoterol Fumarate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Levels of study medication in blood and urine. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety/tolerability |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fluticasone, Formoterol, PK Study, Pharmacokinetics
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?

Study Overview
=================
Brief Summary
-----------------
HIV infection highly increases the risk of progression of latent tuberculosis (TB) to active disease that therapy is recommended for all PPD-positive, HIV-infected patients, regardless of age. Sensitivity of the PPD testing is, however, dependent on a normal T cell function. Therefore, an accurate and reliable method for detection of latent tuberculosis in patients with HIV is urgently needed. This prospective study will examine the utility of interferon-gamma (IFN-γ) based assay, T-SPOT.TB,for detection of TB in HIV-infected individuals.

Official Title
-----------------
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?

Conditions
-----------------
Latent Tuberculosis, HIV Infections

Intervention / Treatment
-----------------
* Other: T-Spot.TB test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria adult individuals with confirmed HIV infection Exclusion Criteria: Patients who are on INH treatment Patients who have a positive PPD test within 1 year of study enrollment Individuals with blistering or ulcerating skin disorder Pregnant women Patients who were given blood transfusion within 6 weeks prior to enrollment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HIV infection<br> | Other: T-Spot.TB test<br>* diagnostic test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
latent tuberculosis, HIV, IFN-γ based assay
VVC Sampling Study for Analysis Validation

Study Overview
=================
Brief Summary
-----------------
This is a biomarker multi-centre study to validate an extraction method of fungal and bacterial DNA extracted from vaginal swabs from adult women with confirmed VVC. The study population will consist of post-menarchal, pre-menopausal females, 18 years or older, seeking care for VVC symptoms. Vaginal samples will be examined under a microscope for yeast forms (hyphae or pseudohyphae) or budding yeast. If the Investigator assesses that the patient has VVC, based on examination and the potassium hydroxide (KOH) test, two vaginal secretion samples will be collected by a vaginal swab. One sample will be cultured to verify the presence of Candida and the other will be used for sequencing analysis of the vaginal microbiome. Samples from a total of 10 women are planned to be taken.

Official Title
-----------------
Collection of Samples From Women Diagnosed With Vulvovaginal Candidiasis for Validation of Vaginal Microbiome Analysis Method

Conditions
-----------------
Vulvovaginal Candidiasis

Intervention / Treatment
-----------------
* Other: No intervention, only sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult women aged 18 years or older Diagnosis of VVC, defined as having a white or creamy vaginal discharge plus the following findings: At least 2 of the following signs and symptoms of VVC that are characterized as at least moderate: itching, burning, irritation, edema, redness, or excoriation. Potassium hydroxide (KOH) or saline preparation from the inflamed vaginal mucosa or secretions revealing yeast forms (hyphae or pseudohyphae) or budding yeasts. Having decisional capacity and providing written informed consent Signed informed consent and willing and able to comply with all study requirements Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention, only sampling|No intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between vaginal sample DNA sequencing and VVC confirmed by clinical diagnosis and culture. |  | 1 day |
Can Hypermobility of First Ray Affect Surgical Treatment of Hallux Valgus

Study Overview
=================
Brief Summary
-----------------
Hallux valgus can be associated with hypermobility of 1st ray. Surgical decision for hallux valgus can be affected by hyper mobility of 1st ray so our clinical trial involved patients with bilateral hallux valgus were planned to underwent fusion of 1st ray and soft tissue correction plus bonionectomy for one foot and for other foot surgical treatment involves corrective osteotomy and soft tissue procedure plus bonionectomy without fusion of 1st tarsometatarsal joint.

Official Title
-----------------
Can Hypermobility of First Ray Affect Surgical Treatment of Hallux Valgus: Randomized Control Trial

Conditions
-----------------
Hallux Valgus

Intervention / Treatment
-----------------
* Procedure: Corrective osteotomy
* Procedure: Fusion of First ray


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hallux Valgus with 1st ray hypermobility Exclusion Criteria: Generalized Ligament laxity Previous foot and ankle surgery Diabetes Mellitus

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Foot with no fusion<br> | Procedure: Corrective osteotomy<br>* First metatarsal distal corrective osteotomy<br>|
| Active Comparator: Foot with fusion<br> | Procedure: Fusion of First ray<br>* Fusion of first ray with soft tissue procedure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| American foot and ankle score | American foot and ankle score involved 9 section | This score was assessed one year after surgery | 
| Foot and Ankle Disability Index | Foot and Ankle Disability Index involved 26 sections | This score was assessed one year after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hallux valgus, First ray hypermobility, Fusion, Corrective osteotomy, Functional outcome
Usage of Stainless Steel Crown on Primary Molars Using Hall Technique

Study Overview
=================
Brief Summary
-----------------
Rationale: Gaining information about the knowledge, practice and attitude regarding hall technique and find out how much the Egyptian dentists use this method for treatment the carious primary teeth. Aim of the study: To assess the knowledge, practice and attitude of Egyptian dentists regarding non invasive restorative approach.

Detailed Description
-----------------
The first study on the Hall Technique was published in 2006 . It was a retrospective study which analysed the practice records of a general dental practitioner from Scotland, Dr. Norna Hall. Dr. Hall simplified the standard technique to restore primary teeth using preformed SSCs and used it with her patients. This retrospective study involved a total of 978 crowns fitted in 259 children using her novel technique (today known as the Hall Technique). Most crowns were placed when there was clinical evidence of a proximal carious lesion into dentine and marginal ridge breakdown. This study showed the Hall Technique to have comparable outcomes to those achieved with other more conventional restorations. Since then, growing understanding that caries is essentially a biofilm driven disease rather than an infectious disease, explains why the Hall Technique, and other 'sealing in' carious lesion techniques, are successful. The intervening ten years has seen robust evidence from several randomised control trials that are either completed or underway. These have found the Hall Technique superior to comparator treatments, with success rates (no pain or infection) of 99% (UK study) and 100% (Germany) at one year, 98% and 93% over two years (UK and Germany) and 97% over five years (UK). The Hall Technique is now regarded as one of several biological management options for carious lesions in primary molars.

Official Title
-----------------
Knowledge, Attitude and Practice (KAP) for Egyptian Pediatric Dentists Regarding Usage of Stainless Steel Crown on Primary Molars Using Hall Technique: A Cross Sectional Study

Conditions
-----------------
Knowledge, Attitudes, Practice

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Egyptian dentists. Pediatric dentists ( having PhD). Pediatric dentists (having Master degree or studying master degree) . Exclusion Criteria: dentists in other dental speciality. dental students. pediatric dentists who have not enough knowledge about hall technique.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| knowledge, practice and attitude of Egyptian Dentists regarding The Hall techniqu | Measuring device: KAP Questionnare Measuring unit: Binary(Yes,No) + Multiple Choice Questions (MCQ). | baseline |
Modification of Posttetanic Count (PTC) for Monitoring Deep Neuromuscular Block II

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the relationship between post-tetanic count (PTC) and time to first response to Train of four (TOF) stimulation during deep neuromuscular blockade induced by rocuronium.

Conditions
-----------------
Neuromuscular Blockade

Intervention / Treatment
-----------------
* Procedure: Post-tetanic count frequency


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA 1-3 General anaesthesia >1 hour Surgery in supine position with possibility of monitoring the neuromuscular blockade at the thumb (n.ulnaris stimulation). Written informed content Exclusion Criteria: Neuromuscular disorders, hepatic and renal dysfunction Medication expected to interfere with the neuromuscular blocking agent Allergy to any medication used during anaesthesia Body weight less or exceeding 20% of the ideal body weight Pregnancy or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Post-tetanic count frequency|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to first response to TOF stimulation (T1) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to second response to TOF stimulation (T2) |  |  | 
| Time to first post-tetanic count (PTC) |  |  | 
| Number of post-tetanic count at first response to TOF |  |  | 
| Time to T1=25% |  |  | 
| Interval 25-75% |  |  | 
| Time to TOF 0.9 |  |  | 
| Time to TOF 1.0 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Train of four, Acceleromyography, TOF-Watch, Posttetanic count, Neuromuscular blockade
Detection of Urinary Human Chorionic Gonadotropin (hCG)

Study Overview
=================
Brief Summary
-----------------
The Mira Pregnancy Test is an over-the-counter urine hCG test intended for early detection of pregnancy. The test is indicated for use four days before the expected period. Throughout this study, volunteers with non-medical backgrounds were recruited to test hCG with urine samples using the Mira Pregnancy Test during the not pregnancy cycle or pregnancy cycle. To perform the study, a total number of more than 200 volunteers will be recruited to participate in the study.

Detailed Description
-----------------
The studies include two parts, which are a lay user study and a urine samples test during the trying to conceive cycle. Part 1: Lay user study Part 2: Detection of hCG in Early Pregnancy Clinical Samples

Official Title
-----------------
Detection of Urinary HCG During The Not Pregnancy and Pregnancy Cycles

Conditions
-----------------
Pregnancy Detection

Intervention / Treatment
-----------------
* Device: Daily test with urine by the product


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female Aged 18 and over Willing to give informed consent Willing to conduct a personal home pregnancy test and reveal their pregnancy status Have a working smartphone Exclusion Criteria: Have a medical background or have been in a related industry/occupation Volunteers who are unfit to participate in the research by the researcher Used the investigational pregnancy test previously Has a medical condition Confirmed to be pregnant by a healthcare professional and beyond the first trimester (defined as last menstrual period (LMP) +13 weeks)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women who are trying to conceive<br> | Device: Daily test with urine by the product<br>* Women perform the hCG test and share the test results<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive evaluation via survey and calculating the consistency | The consistency between the lay-user test results and the actual test results | From July 2022 to August 2022 | 
| The accuracy of data was expressed as per the Pregnancy Detection Rate | The number of positive results on different days obtained by the user of the Mira pregnancy test is divided by the total number of women who confirmed pregnancy. | From July 2022 to August 2022 |
Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to determine the safety of hMN14 at different dose levels in the treatment of either colorectal or breast cancer.

Official Title
-----------------
A Phase I/II Clinical Trial of Immunotherapy With Humanized MN-14 IgG in Recurrent, Metastatic, Unresectable Colorectal and Breast Carcinomas

Conditions
-----------------
Colorectal Cancer, Colon Cancer, Rectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Breast Cancer, Breast Neoplasms

Intervention / Treatment
-----------------
* Drug: hMN14 (labetuzumab)


Participation Criteria
=================
Eligibility Criteria
-----------------
Disease Characteristics: Histologic or cytologic diagnosis or either, colonic, rectal, or breast carcinoma Measurable lesion diagnosed by CT scan Recurrent/metastatic disease considered surgically unresectable. Prior/Concurrent Therapy: Chemotherapy: Patients who either have failed at least one regimen of standard systemic therapy, or are clinically asymptomatic and are not presently being considered for chemotherapy (Enrollment must occur at least 4 weeks beyond last treatment) Other: Prior treatment with investigational agents is excluded unless follow-up is completed and patient is off study Patient Characteristics/Inclusion Criteria: Performance Status: Patients with a Karnofsky performance status > 70% (or equivalent, ECOG 0-1) and expected survival of at least 3 months. Hematopoietic: WBC >/= 3000 mm3, neutrophils >/= 1500 mm3, platelets >/= 75,000, CEA < 300 ng/mL Hepatic: Serum bilirubin </= 2.0 mg/dL, ALT < 2.5 x IULN Cardiovascular: Patients with LVEF >/= 40% by required MUGA/2D-ECHO study. Pulmonary: Patients with FEV1 >/= 60% by required Pulmonary Function Tests Other: Patients agreeing to use a medically effective method of contraception during and for a period of 3 months after the treatment period. A pregnancy test will be preformed on each premenopausal female of childbearing potential immediately prior to entry into the study. Patients able to understand and give written informed consent. Patients with a significant concurrent medical condition that could affect the patient's ability to tolerate or complete the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: hMN14 (labetuzumab)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colorectal Cancer, Colon Cancer, Rectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Breast Cancer, Breast Neoplasms